Necrotizing Subcutaneous Infection

Interleukin 6 IL 6 Receptor IL 6R

Although the causes of rheumatoid arthritis are not fully understood, constitutive overproduction of interleukin-6 (IL-6), a multifunctional cytokine that regulates immune response, inflammatory react...

Obesity

Obesity is the condition in which excess fat has accumulated in the body (mostly in subcutaneous tissues). clinical obesity is considered to be present when a person has a BMI of over 30 (Oxford Dic...

Anthrax Vaccines and Therapeutics

Anthrax is a zoonotic disease caused by the spore-forming bacterium Bacillus anthracis. The disease most commonly occurs in mammals (e.g., cattle, sheep, goats, camels, antelope. Anthrax occurs in hu...

CD20 Antibodies

The chimeric anti-CD20 antibody rituximab (Rituxan & MabThera) from Biogen Idec and Genentech/Roche is one of the world’s commercially most successful antibodies (2007 sales of over US$ 5 bl...

Roche reports second positive study of RoACTEMRA given by subcutaneous injection to patients with rheumatoid arthritis

Roche today announced that the BREVACTA study of RoACTEMRA (tocilizumab, known as ACTEMRA outside Europe) given as a subcutaneous (SC) injection to patients with rheumatoid arthritis (RA) met its prim...

Treating KSHV-Associated Multicentric Castleman Disease

In this pilot study, patients with KSHV-associated multicentric Castleman disease will receive intravenous tocilizumab every other week for up to 12 weeks. Patients who do not benefit from tocilizumab...

CHMP Recommends Extended Use of Tocilizumab

The EMA committee has recommended extending the indication for tocilizumab to children with juvenile idiopathic polyarthritis who fail methotrexate. International Approvals

Roche reports second positive study of RoACTEMRA

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the BREVACTA study of RoACTEMRA (tocilizumab, known as ACTEMRA outside Europe) given as a subcutaneous (SC) injection to patients with rheumatoid arth...

Tocilizumab Effective In Juvenile Idiopathic Arthritis

A new study presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism shows that tocilizumab is efficacious and leads to a sustained clinically meaningful improvement in c...

Genentech Actemra meets primary endpoint in BREVACTA study

Genentech, a member of the Roche Group, has reported positive results from the BREVACTA study of Actemra (tocilizumab) given by subcutaneous injection to rheumatoid arthritis (RA) patients.

Genentech to file sc Actemra in US for RA in 2012

Reporting positive results from a second trial investigating a subcutaneous (sc) formulation of its rheumatoid arthritis (RA) treatment, Actemra (tocilizumab; also known as RoActemra), Roche's Genen...

Subcutaneous Actemra meets Phase III RA endpoint

Roche (SIX:ROG; OTCQX:RHHBY) said subcutaneous Actemra tocilizumab given every two weeks met the primary endpoint of ACR20 response rate at week 24 vs. placebo in the Phase III BREVACTA trial to treat...

A case report of a patient with rheumatoid arthritis complicated with Mycobacterium avium during tocilizumab treatment.

A female patient with rheumatoid arthritis (RA) suffered from Mycobacterium avium (M. avium) infection during tocilizumab treatment. Tocilizumab was discontinued and she was treated with a recommended...

Nodular progression of lentigo malignant melanoma during a treatment with tocilizumab: cause or coincidence?

Tocilizumab is an anti-interleukin (IL)-6 receptor monoclonal antibody, used since 2010 for the treatment of severe rheumatoid arthritis (RA). It is known to induce infection, similarly to other bioth...

Case report: successful use of short-term add-on tocilizumab for multirefractory systemic flare of adult-onset Still's disease.

We report on a 64-year-old woman with multirefractory flare of adult-onset Still's disease successfully treated with six-month course of add-on anti-interleukin 6 receptor antibody, tocilizumab. Befor...

Benefit and a possible risk of tocilizumab therapy for adult-onset Still's disease accompanied by macrophage-activation syndrome.

We report a 57-year-old female case of intractable adult-onset Still's disease (AOSD). Initial high-dose prednisolone therapy was ineffective, and macrophage-activation syndrome (MAS) manifested after...

Tocilizumab in the treatment of the adult-onset Still's disease: current clinical evidence.

This study aimed to review and analyze the effectiveness and safety of tocilizumab in the treatment of patients with adult-onset Still's disease (AOSD). We report on two patients with AOSD who were su...